Hyper-inflammation and skin destruction mediated by rosiglitazone activation of macrophages in IL-6 deficiency

Journal of Investigative Dermatology

Volumn 135, Issue 2, 2015, Pages 389-399

  Das, Lopa M ^a   Rosenjack, Julie ^a   Au, Liemin ^a   Galle, Pia S ^b   Hansen, Morten B ^b   Cathcart, Martha K ^c   McCormick, Thomas S ^a   Cooper, Kevin D ^a   Silverstein, Roy L ^d   Lu, Kurt Q ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD11B ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; 2,4 THIAZOLIDINEDIONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN-6, MOUSE; NOS2 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL INFILTRATION; CHRONIC WOUND; CONTROLLED STUDY; DERMATITIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; POLARIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN DEFECT; UPREGULATION; WOUND HEALING IMPAIRMENT; ANIMAL; C3H MOUSE; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; INFLAMMATION; PATHOLOGY; PHYSIOLOGY; SKIN; WOUND HEALING;

ANIMALS; FEMALE; INFLAMMATION; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; SKIN; STAT3 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; WOUND HEALING;

EID: 84930182637     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.375     Document Type: Article

References (55)

1. Akiyama H, Barger S, Barnum S et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421
2. Awazawa M, Ueki K, Inabe K et al. (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13:401-12
3. Baadsgaard O, Wulf HC, Wantzin GL et al. (1987) UVB and UVC, but not UVA, potently induce the appearance of T6- DR + antigen-presenting cells in human epidermis. J Invest Dermatol 89:113-8
4. Campanholle G, Landgraf RG, Goncalves GM et al. (2010) Lung inflammation is induced by renal ischemia and reperfusion injury as part of the systemic inflammatory syndrome. Inflamm Res 59:861-9
5. Chatterjee PK (2010) Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol 160:1889-91
6. Chomarat P, Banchereau J, Davoust J et al. (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1:510-4
7. Ciapponi L, Maione D, Scoumanne A et al. (1997) Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol 15:997-1001
8. Curran RD, Billiar TR, Stuehr DJ et al. (1989) Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products of Kupffer cells. J Exp Med 170:1769-74
9. Cuzzocrea S, Pisano B, Dugo L et al. (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483:79-93
10. Faveeuw C, Fougeray S, Angeli V et al. (2000) Peroxisome proliferatoractivated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 486:261-6
11. Feinstein DL, Spagnolo A, Akar C et al. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70:177-88
12. Fosgerau K, Galle P, Hansen T et al. (2010) Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J Endocrinol 204:265-73
13. Fujiwara N, Kobayashi K (2005) Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 4:281-6
14. Galle P, Jensen L, Andersson C et al. (2007) Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int Immunopharmacol 7:1704-13
15. Galle P, Svenson M, Bendtzen K et al. (2004) High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol 34:3267-75
16. Gregorio J, Meller S, Conrad C et al. (2010) Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med 207:2921-30
17. Hammad H, de Heer HJ, Soullie T et al. (2004) Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 164:263-71
18. Hammerberg C, Duraiswamy N, Cooper KD (1996) Reversal of immunosuppression inducible through ultraviolet-exposed skin by in vivo anti-CD11b treatment. J Immunol 157:5254-61
19. Hansen MB, Svenson M, Diamant M et al. (1991) Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 33:777-81
20. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-95
21. Harbrecht BG, Nweze I, Smith JW et al. (2012) Insulin inhibits hepatocyte iNOS expression induced by cytokines by an Akt-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 302:G116-22
22. Hasegawa-Moriyama M, Ohnou T, Godai K et al. (2012) Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization. Biochem Biophys Res Commun 426:76-82
23. Hotchkiss RS, Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813-22
24. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-6
25. Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1:a001651
26. Li Y, de Haar C, Peppelenbosch MP et al. (2012) SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Cytokine Growth Factor Rev 23:127-38
27. Liu H, Wang S, Sun A et al. (2012) Danhong inhibits oxidized low-density lipoprotein-induced immune maturation of dentritic cells via a peroxisome proliferator activated receptor gamma-mediated pathway. J Pharmacol Sci 119:1-9
28. Lovibond AC, Haque SJ, Chambers TJ et al. (2003) TGF-beta-induced SOCS3 expression augments TNF-alpha-induced osteoclast formation. Biochem Biophys Res Commun 309:762-7
29. Lowry JL, Brovkovych V, Zhang Y et al. (2013) Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthaselike output of nitric oxide in inflamed endothelium. J Biol Chem 288:4174-93
30. Mao K, Chen S, Chen M et al. (2013) Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res 23:201-12
31. Marinescu VD, Kohane IS, Riva A (2005) The MAPPER database: a multigenome catalog of putative transcription factor binding sites. Nucleic Acids Res 33:D91-7
32. Meunier L, Bata-Csorgo Z, Cooper KD (1995) In human dermis, ultraviolet radiation induces expansion of a CD36 + CD11b + CD1- macrophage subset by infiltration and proliferation; CD1 + Langerhans-like dendritic antigen-presenting cells are concomitantly depleted. J Invest Dermatol 105:782-8
33. Nagy L, Tontonoz P, Alvarez JG et al. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma. Cell 93:229-40
34. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al. (2007) Macrophagespecific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116-20
35. Pahan K, Sheikh FG, Liu X et al. (2001) Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J Biol Chem 276:7899-905
36. Park EJ, Park SY, Joe EH et al. (2003) 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 278:14747-52
37. Pearson TA, Mensah GA, Alexander RW et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
38. Puel A, Picard C, Lorrot M et al. (2008) Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 180:647-54
39. Qi F, Adair A, Ferenbach D et al. (2008) Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation 86:1267-74
40. Qin H, Yeh WI, De Sarno P et al. (2012) Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc Natl Acad Sci USA 109:5004-9
41. Ricote M, Li AC, Willson TM et al. (1998) The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
42. Rosen CJ (2007) The rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844-6
43. Sener G, Sehirli AO, Gedik N et al. (2007) Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 33:587-93
44. Sikora JP, Chlebna-Sokol D, Andrzejewska E et al. (2008) Clinical evaluation of proinflammatory cytokine inhibitors (sTNFR I, sTNFR II, IL-1 ra), anti-inflammatory cytokines (IL-10, IL-13) and activation of neutrophils after burn-induced inflammation. Scand J Immunol 68:145-52
45. Sikora JP, Kuzanski W, Andrzejewska E (2009) Soluble cytokine receptors sTNFR I and sTNFR II, receptor antagonist IL-1ra, and anti-inflammatory cytokines IL-10 and IL-13 in the pathogenesis of systemic inflammatory response syndrome in the course of burns in children. Med Sci Monit 15:CR26-31
46. Takemura H, Suzuki H, Yoshizaki K et al. (1992) Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 35:940-3
47. Tanaka T, Kishimoto T (2012) Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 8:1227-36
48. Tilg H, Trehu E, Atkins MB et al. (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-8
49. Tsukahara Y, Morisaki T, Kojima M et al. (2001) iNOS expression by activated neutrophils from patients with sepsis. ANZ J Surg 71:15-20
50. Tsukamoto H, Hishinuma T, Suzuki N et al. (2004) Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. Prostaglandins Other Lipid Mediat 73:191-213
51. Wheeler JL, Martin KC, Lawrence BP (2013) Novel cellular targets of AhR underlie alterations in neutrophilic inflammation and inducible nitric oxide synthase expression during influenza virus infection. J Immunol 190:659-68
52. Xing Z, Gauldie J, Cox G et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101:311-20
53. Xu B, Bhattacharjee A, Roy B et al. (2003) Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3. Mol Cell Biol 23:3918-28
54. Yu Z, Kone BC (2004) The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and iuducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol 15:585-91
55. Yu Z, Zhang W, Kone BC (2002) Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367:97-105